Entera Bio Q1 net loss $2.6M ($0.06/sh); cash runway to mid-Q3 2026; pipeline advances

Entera Bio Ltd.

2025-Q1 EPS reported $0.06 revenue$42,000

Net loss of $2.6M ($0.06 per share) for Q1 2025 vs $2.0M ($0.05) in Q1 2024; operating expenses $2.6M.
Cash and equivalents $20.6M as of Mar 31, 2025; expects to fund operations through mid-Q3 2026.
EB613 (oral PTH) bone data presented at WCO-IOF-ESCEO Apr 2025; Next Gen EB613 Phase 1 planned H2 2025.
Collaboration with OPKO for oral GLP-1/Glucagon program; IND filing planned late 2025/early 2026.
Appointed Cherin Smith as EVP Clinical Ops (Mar) and Leslie Gautam as CBO (May 2025).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.